BioprocessUpdates’ Post

🔬 Reflecting on a tough 2023 & Eagerly Awaiting a Bright 2024 in Biotech! 💪🧬 2023 posed challenges for biotech with 27 closures— a stark rise from 7 in 2022. Flagship Pioneering's Rubius Therapeutics, Tessa Therapeutics Ltd, Cyteir Therapeutics, Antios Therapeutics, and Sorrento Therapeutics, Inc. faced unique hurdles, demonstrating the industry's demand for resilience. Despite closures, the biotech community showcased adaptability. Fundraising got tougher, but Pharma and biotech deals rose by 35% in 2023. 2024 brings hope with collaborations like RayzeBio-Bristol Myers Squibb and the $43B Seagen-Pfizer partnership still taking place towards the back end of the year. Will JPM Conference be the catalyst for VCs and big pharma in 2024? A lot of people seem to think so! 😁 #Biotech #Innovation #2023Reflections #2024Outlook #JPMConference #ResilienceInBiotech #JPM

Alberto Loche and I had the great honor to convene the McKinsey CGT expert panel at the #jpm2024 conference with Lynelle Hoch (BMS), Jak Knowles (Affini-T Therapeutics), Fabian Gerlinghaus (Cellares), Peter Olagunju (March Biosciences), and Cindy Perettie (Kite, A Gilead Company). Thanks all for such an insightful discussion and stay tuned for more insights coming out soon! #biotech #CGT #innovation #mckinseyinsights

Diagonal Therapeutics has successfully announced its launch, raising $128 Million through a Series A financing round for its new approach to discovering & developing agonist antibodies. 👏 💥 President & CEO (Alexey "Alex" Lugovskoy) mentioned last week that the proceeds will enabled the advancement of our pipeline of antibody agonists discovered by the DIAGONAL platform, including our lead program that treats the root cause of hereditary hemorrhagic telangiectasia, a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. ✨ BVF PARTNERS, L.P & Atlas Venture successfully led the Series A financing round with participation from Checkpoint Capital, LLC., Frazier Life Sciences, Lightspeed, RA Capital Management, Velosity Capital and Viking Global Investors. 💲💲💲 #Elixir #Announcement #Biotech #Pharma #Healthcare #Funding #SeriesA #Innovation #CompanyLaunch #Antibody #LifeSciences #Investment

With two deals in six days, AbbVie has now inked the 3rd and 4th largest biopharma acquisitions of 2023 so far: Oct. 5: $110 million upfront for Parkinson's disease startup Mitokinin Nov. 30: $10.1 billion for decades-old ADC maker ImmunoGen Dec. 6: $8.7 billion for neuroscience biotech Cerevel Therapeutics CEO Rick Gonzalez hinted at the Chicago-area Big Pharma's appetite for more deals when discussing the ImmunoGen acquisition last Friday when he told analysts: "We have the financial wherewithal to do that if we found another asset that looked like this in neuroscience or anywhere else. We would act on it.” #abbvie #cerevel #pharma #biotech #acquisitions #mergersandacquisitions #dealmaking #drugdevelopment #neuroscienceresearch #schizophrenia #parkinsonsdisease Endpoints News

As September comes to an end, let’s revisit some of our favorite moments. Earlier this month, Gift of Life Biologics participated in #AdvancedTherapiesEurope in Portugal, where we had the opportunity to connect with leaders in the industry. 🎤The standout moment of the event occurred when our CEO, Eric Strati, Pharm.D., took the stage alongside Cellex Cell Professionals 🫱🏼🫲🏻Together, they shared valuable insights on fostering international collaborations to support the development of donor-derived #celltherapy. What’s your September highlight? Share it below! ⬇️ #GeneTherapy #BloodCancers #LeadersInCellTherapy

It appears that big pharma isn't the only party interested in the success of the anticoagulant Xarelto. Blackstone, a leading private equity firm, has made a $250 million investment in Anthos Therapeutics, a biotech firm that is developing an alternative to Xarelto. The investment is a testament to the potential of Anthos' therapy, which recently successfully achieved the necessary endpoints on its Phase 2 clinical trial for major bleeding. The trial results are promising: Anthos' therapy was found to be safe and effective in treating major bleeding. It also showed a decrease in the rate of re-bleeding. mAnthos is now in the process of applying for approval from the FDA. If approved, the therapy could be an alternative to Xarelto, which is currently the only drug approved for major bleeding. #Biotech #majorbleeding #Blackstone #FTSE100

Ajax Therapeutics Raises $95m Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic https://lnkd.in/g5dJfqRM Ajax Therapeutics Goldman Sachs Alternatives Eli Lilly and Company Vivo Capital RA Capital Management Point72 Ventures EcoR1 Capital, LLC Boxer Capital, LLC Schrödinger inning one ventures Amit Sinha Ming Cheah, PhD Martin Vogelbaum More US Life Science Business News at [LSUS] Life-Sciences-USA.com .

Deals are finally starting to happen

👀 Looking for innovative treatment for #HPV-associated cancers? 🥇 RDP Pharma AG has identified a first-in-class, orally available, small molecule-based new chemical entity, monovalent protein degrader which induces the proteolysis of the human papillomavirus (HPV)-associated E7 oncoprotein. 💊 Single-agent efficacy of the asset has been demonstrated in an HPV-dependent cervical cancer xenograft model. It revealed clear single-agent degradation and consequent inhibition of E7 activity. Additionally, and highly promising, no toxicity has been observed in mice. 🚀 We are excited to have RDP Pharma AG listed their innovative drug candidate on Bioneex. Curious to learn more about the innovative drug candidate? Join Bioneex to further explore partnership, in-licensing, and investment opportunities: https://bioneex.com. #HPV #cancers #E7 #oncoprotein #pharma #biotechnology #biopharma #healthcare #clinicaltrials #innovation #firstinclass #smallmolecule #NCE #newchemicalentity #Bioneex #RDPPharma

CS Sheffield, widely known as Sheff from Sheff Station, joins us on April 3rd at 12pm ET to discuss what he looks for when analyzing biotech companies, catalysts, and to discuss the current biotech landscape. CS was a former executive at Merck and Pfizer for a combined 27 years in their oncology division and has been investing in biotech for 18 years. We are very much looking forward to the discussion! Please register via the link below: https://lnkd.in/dhZYMDVN #webinar #biotech #tradingbiotech #biotechinvesting #pharma #betherewhenithappens #catalysts